United States: FDA Publishes Redraft Of 510(K) Third Party Review Program

Last Updated: November 23 2018
Article by Frederick Ball

Redraft of 510(k) Third Party Review Program

The proposed plan will permit the FDA to focus its resources on higher-risk and complex devices.

Section 523 of the Federal Food, Drug, and Cosmetic (FD&C) Act codifies the 510(k) Third Party Review Program (3P Review Program), which authorizes certain qualified third parties (3P Review Organizations) to conduct the initial review of premarket notification submissions for certain low-to-moderate risk medical devices. The 3P Review Program has been in existence since 1996, and the Food and Drug Administration (FDA) has modified aspects of the 3P Review Program from time to time to comply with changes in the statutory framework. The FDA Reauthorization Act of 2017 (FDARA), which was signed into law on August 18, 2017, amended Section 523. In response, the FDA has now published a draft guidance, titled "510(k) Third Party Review Program Draft Guidance for Industry, Food and Drug Administration Staff, and Third Party Review Organizations," which modifies the 3P Review Program guidance. Comments and suggestions are due by December 13, 2018. When finalized, this guidance will supersede FDA's guidance documents from 2001 and 2004.

The objectives set forth in the draft guidance are to outline: (1) the factors FDA will use in determining device type eligibility; (2) the FDA's process for the recognition, rerecognition, suspension and withdrawal of recognition for 3P Review Organizations; and (3) steps toward consistent quality of work among 3P Review Organizations.

According to the draft guidance, the 3P Review Program will allow the FDA to focus its internal scientific review resources on higher-risk and complex devices, while confidently depending on the 3P Review Organizations for the review of low-to-moderate risk and less complex devices. Participation in the 3P Review Program is voluntary. The guidance lists a number of factors for determining device eligibility, which include:

  • The risk posed by a given type of device (class III devices, for example, are not eligible); whether the device is permanently implantable, life sustaining, or life supporting;
  • The extent to which the device type is well understood;
  • Whether the information materially relevant to evaluating the submission is proprietary and cannot be shared outside the agency;
  • Whether multifaceted and interdisciplinary expertise is necessary for review (certain clinical data or complex non-clinical data, multi-reader clinical studies, combination products or device types, and devices needing cross-labeling considerations are ineligible); and
  • The availability of post-marketing data implicating safety. 

The guidance also notes that FDA will periodically update the product code classification data base and list of devices eligible for 3P Review.

The guidance makes recommendations regarding review made by the 3P Review Organizations, which the guidance characterizes to "share FDA's mission to protect and promote the public health by ensuring medical devices are safe and effective for their intended uses." The FDA suggests the 3P Review Organization take the following steps: determine whether the device type is eligible for 3P review; assign Product Specialist(s) and Technical Expert(s) with the appropriate education, training, technical knowledge and the like for the device type(s) the organization will review; obtain and be familiar relevant FDA guidance(s) and information (such as guidances, special controls, postmarket databases, premarket review information in FDA's 510(k) database, and standards); ensure the submission is administratively complete; conduct a substantive review of the submission; and make a final recommendation to the FDA by preparing a review documentation that specifying the reasoning and steps that led to the final determination for the submission. The FDA promotes early consultation with the FDA, if needed. The FDA expects 3P Review Organizations to identify any deficiencies and document the reasoning and steps that led to their final recommendation, and provide additional information upon FDA's request. If a 3P Review Organization submits a 510(k) to FDA for an ineligible device or a device that organization is not recognized to review, the FDA will place the submission on a hold. If the 3P Review Organization does not address the eligibility concerns or withdraw the submission within 180 days, FDA will delete the file. A 510(k) Submitter cannot submit a 510(k) for the same device directly to FDA until the 3P Review Organization's submission is withdrawn voluntarily by the organization or is automatically deleted by FDA.

As a step toward consistent quality of work among 3P Review Organizations, the guidance focuses on the requirements recognition and rerecognition of the 3P Review Organizations. The criteria for recognition or rerecognition include that the 3P Review Organization must be an independent organization that is controlled neither by the federal government nor by a manufacturer, supplier, or vendor of devices or the like, making them impartial and free from any commercial, financial, and other pressures that might present a conflict of interest. The guidance provides that the personnel retained by the 3P Review Organization must have relevant knowledge and experience for the devices that the 3P Review Organization is recognized to review. The guidance states that the 3P Review Organizations will be expected to consult national and/or international standards recognized by FDA as well as FDA guidance documents. The guidance provides steps for obtaining recognition as a 3P Review Organization. The recognition sunsets after three years and obtaining rerecognition would be required to continue functioning as a 3P Review Organization.

Finally, the guidance provides details for complying with the International Medical Device Regulators Forum's (IMDRF) requirements for the Medical Device Single Audit Program (MDSAP). There are many similarities between these regimes, and the draft guidance provides a side-by-side comparison for leveraging existing documentation of applications submitted to FDA. 

In summary, the proposed plan will permit the FDA to focus its resources on higher-risk and complex devices. It also provides guidance for identifying device types that are eligible for the 3P Review Program, as well as provides systematic guidance for the 3P Review Organizations for conducting review and improving quality of the 3P Review Program. 

For Further Information

If you have any questions about this Alert, please contact Frederick R. Ball, Carolyn A. Alenci, any of the attorneys in our Life Sciences Group or the attorney in the firm with whom you are regularly in contact. 

Disclaimer: This Alert has been prepared and published for informational purposes only and is not offered, nor should be construed, as legal advice. For more information, please see the firm's full disclaimer.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions